Background. Loin pain haematuria syndrome (LPHS) and autosomal dominant polycystic kidney disease (ADPKD) are the most important non-urological conditions to cause chronic severe kidney-related pain. Multidisciplinary programmes and surgical methods have shown inconsistent results with respect to pain reduction. Percutaneous catheter-based renal denervation (RDN) could be a less invasive treatment option for these patients. Methods. Our aim was to explore the change in perceived pain and use of analgesic medication from baseline to 3, 6 and 12 months after RDN. Patients with LPHS or ADPKD, who experienced kidney-related pain !3 months with a visual analogue scale (VAS) score ! 50/100 could be included. Percutaneous RDN was performed with a single-electrode radiofrequency ablation catheter. Results. RDN was performed in 11 patients (6 with LPHS and 5 with ADPKD). Perceived pain declined in the whole group by 23 mm (P ¼ 0.012 for the total group). In patients with LPHS and ADPKD, the median daily defined dosage of analgesic medication decreased from 1.6 [interquartile range (IQR) 0.7-2.3] and 1.4 (IQR 0.0-7.4) at baseline to 0.3 (IQR 0.0-1.9; P ¼ 0.138) and 0.0 (IQR 0.0-0.8; P ¼ 0.285) at 12 months, respectively. Mean estimated glomerular filtration rate decreased in the whole group by 5.4 mL/min/1.73 m 2 at 6 months compared with baseline (P ¼ 0.163). Conclusions. These results suggest that percutaneous catheterbased RDN reduces pain complaints and the use of analgesic medication in patients with LPHS or ADPKD. The present results can serve as the rationale for a larger, preferably randomized (sham) controlled study.
I N T R O D U C T I O N
Loin pain haematuria syndrome (LPHS) and autosomal dominant polycystic kidney disease (ADPKD) are the most important non-urological conditions to cause kidney-related pain. LPHS is a rare disease and a diagnosis by exclusion. Patients often experience intense, sometimes invalidating unilateral or bilateral flank pain >6 months and haematuria (with or without dysmorphic erythrocytes). This disease can be associated with glomerulonephritis, usually IgA nephropathy [1] . Pain in LPHS is thought to be caused by tubular obstruction due to erythrocytes and/or microcrystals, which leads to capsular distension and, eventually, visceral pain [2, 3] . LPHS is usually not associated with deterioration in kidney function, infection or hypertension [3, 4] .
ADPKD is a leading cause of end-stage renal disease in Europe [5] . Patients with ADPKD can experience invalidating pain, which may be caused by distension of the renal capsule caused by expansion of renal cysts, which causes visceral pain [6] . Chronic pain in LPHS and ADPKD is sometimes difficult to treat. Often, analgesic medication is necessary to control the pain, in many cases also including opioids [7] . Surgical procedures such as nephrectomy, renal autotransplantation or laparoscopic renal denervation (RDN) have proven to be effective in pain relief [3, 8] . However, these procedures are invasive and nephrectomy of a still functioning kidney will put the patient at greater risk for end-stage kidney disease, especially in ADPKD.
Catheter-based RDN was introduced as a possible treatment of apparent resistant hypertension [9] . It aims to disrupt the renal sympathetic nerves by using variable methodologies within the renal arteries, including radiofrequency, intravascular ultrasound and local application of neurotoxic agents, such as ethanol [10] [11] [12] [13] [14] . Conceptually, catheter-based RDN may be an attractive option for treating kidney-related pain, as the majority of pain-conducting nerve fibres are located circumferentially around the renal artery and the hilum [4, 15] . At present, there are some case reports that suggest a beneficial effect of catheter-based RDN in LPHS [16] [17] [18] [19] . In addition, we published a case report on the effects of catheter-based RDN in a patient with ADPKD on both sides with a tremendous decrease in perceived pain [16] .
Our aim was to study the effect of catheter-based RDN on perceived pain and the use of analgesic medication in patients with LPHS or ADPKD with kidney-related pain in a larger group of patients to guide further research. Second, we summariz available evidence in the literature.
M A T E R I A L S A N D M E T H O D S
This pilot study was designed as a prospective cohort. Patients were referred to our department by colleagues of our own hospital and from other centres across The Netherlands between May 2013 and April 2015. Patients had either kidney-related pain due to LPHS or ADPKD. All LPHS patients had a history of urological and nephrological analysis to rule out other treatable causes of their complaints, as well as consultation of a pain specialist and/or psychologist. Patients with ADPKD were thoroughly screened for other causes of pain, as they participated in a study that investigated the effect of sequential nerve blocks on pain relief in ADPKD patients with refractory chronic pain. As a first step, a diagnostic temporary celiac plexus block with local anaesthetics was performed [20] . In case there was no pain relief after this nerve block, we assumed that the pain stimuli relayed via the aortico-renal plexus and RDN could be an option. All patients were discussed in a multidisciplinary setting [21] . They were considered eligible for RDN if they were !18 years old, had invalidating kidney-related pain [!3 months pain duration, !50/100 on a visual analogue scale (VAS) and insufficient response to previous analgesic therapies] and when a computer tomography angiogram or magnetic resonance angiogram showed a diameter >4 mm and a length >20 mm of the renal artery at the side of the pain. All patients gave their permission to be part of this study, in accordance with the Declaration of Helsinki.
Pain assessment
Based on the McGill Pain Questionnaire (MPQ), the validated Dutch questionnaire (MPQ-DV) was used to assess perceived pain [22, 23] . In this questionnaire, patients were asked to fill out their maximal VAS score. The VAS score is the maximum pain a patient has experienced in the last 2 weeks on a scale from 0 (no pain at all) to 100 mm (maximum of pain possible). Patients were asked to fill out the questionnaire at baseline (pre-RDN) and 3, 6 and 12 months post-RDN.
Analgesic use assessment
Medication was screened for analgesic medication, according to the Anatomical Therapeutic Chemical (ATC) classification system of the World Health Organization Collaborating Centre for Drug Statistics (http://www.whocc.no/atc_ddd_ index/) at baseline and 3, 6 and 12 months. We registered the number of different classes of analgesics and we calculated the total daily defined dose (DDD) of analgesic medication per patient per visit.
Kidney function and blood pressure assessment
At baseline and 6 months, the estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [24] . Office blood pressure measurements were collected at baseline and at 6 months and calculated as the average of three measurements on each arm. All blood pressure measurements were done with methods and devices in accordance with the latest recommendations of the European Hypertension Consensus [25] .
RDN
The University Medical Center Utrecht is a European Society of Hypertension centre of excellence and participated in a number of RDN trials for hypertension. Detailed information on the procedure has been published elsewhere [26, 27] . The procedure was performed by an experienced interventionist using the radiofrequency ablation Symplicity catheter (Medtronic Santa Rosa, CA, USA) only in the renal arteries located on the side where the patient experienced pain. The interventionist decided on the number of ablations and if all (accessory) arteries could be treated on that particular side. When the patient experienced pain on both sides, the side with the highest VAS score would be treated first and 3 months later the other side if no procedural complications had occurred the first time. Adverse events were collected at follow-up.
Statistical analysis
Normally distributed variables are expressed as mean 6 SD, whereas non-normally distributed variables are reported as median [interquartile range(IQR)]. Changes in VAS score, analgesics used and DDD between baseline and follow-up were analysed with the Wilcoxon signed-rank test. Changes were analysed for the whole group as well as stratified for ADPKD and LPHS. Paired t-test analysis was used to analyse changes in blood pressure and eGFR between baseline and 6 months. A two-tailed P-value <0.05 was considered to indicate statistical significance. All statistical analyses were performed using SPSS Statistics for Windows, Version 21.0 (IBM Armonk, NY, USA).
Pooling data of other published case reports
PubMed and EMBASE were searched for case reports assessing RDN and the effect on pain relief in patients with LPHS and ADPKD. The following broad search terms were used to cover all the aspects, as we hypothesized that there would only be small series and case reports available: kidney pain, renal denervation, autosomal dominant polycystic kidney disease, ADPKD, loin pain hematuria syndrome, LPHS. Eligible for inclusion were reports of kidney-related pain and percutaneous catheter-based RDN. We extracted, if possible, data on change in perceived pain and in analgesic medication between baseline and 6 and 12 months follow-up.
R E S U L T S Baseline characteristics
Eleven patients with kidney-related pain were included: six patients with LPHS and five patients with ADPKD ( Table 1) . The mean age was 40 6 9 years and 9 of the 11 patients were female. All patients with ADPKD and one LPHS patient used antihypertensive medication. Kidney function was impaired in the ADPKD group as compared with the LPHS group (eGFR 51 6 31 versus 117 6 15 mL/min/1.73 m 2 ). The median duration of chronic pain was longer in the ADPKD group [4.0 (IQR 2.4-19.5) years] as compared with 1.5 (IQR 0.5-6.5) years in the LPHS group. Fifty-five percent of all patients experienced pain at the right side. The LPHS group noted the highest pain experience, with a median VAS score of 84 (IQR 77-94) mm compared with 76 (IQR 64-86) mm in the ADPKD group. In addition, patients in the LPHS group used, on average, one class of analgesic medication more than patients in the ADPKD group (3.0 versus 2.0 pills). Fifty-five percent of the patients (n ¼ 6) used some type of opioid daily as treatment for their pain.
Change in perceived pain after RDN RDN was performed on both sides in two patients and unilaterally in nine. The mean number of ablations per kidney was 761. There were no serious adverse events reported after the procedure. Supplementary data, Figure S1 represents the individual data of the VAS score per patient group (LPHS and ADPKD). Perceived pain declined in the overall population from 82 (IQR 70-92) mm to 68 (IQR 55-79) mm (P ¼ 0.036) and 59 (IQR 0-71) mm (P ¼ 0.012) at 3 and 12 months after RDN, respectively. The decrease was consistent in both groups (Table 2) .
Change in the use of analgesic medication after RDN
In the whole group the median number of classes of analgesic medication decreased significantly from 2.0 (IQR 2.0-3.0) at baseline to 1.5 (IQR 0.8-2.3) at 3 months (P ¼ 0.033) and decreased slightly further at 12 months to 1.0 (IQR 0.0-2.0) (P ¼ 0.011) ( Table 2 ). Supplementary data, Figure S2 represents the individual data of the DDD of analgesic medication. Overall, a reduction in DDD was seen from 1.4 (IQR 0.4-2.1) at baseline to 0.6 (IQR 0.3-1.4) and 0.0 (IQR 0.0-1.6) at 3 and 12 months (P ¼ 0.018 and 0.068, respectively). In the LPHS group, the DDD was reduced from 1. 
Kidney function and blood pressure
Supplementary data, Figure S3 shows the available data on eGFR in each individual patient (n ¼ Table S1 ). The change seems to be mainly caused by one LPHS patient (Supplementary data, Figure S3 ). In the ADPKD group, office systolic blood pressure declined at 6 months, with a mean of 5 6 6 mmHg compared with baseline, accompanied by a median reduction in the use of blood pressure-lowering drugs of 1.5 pills. The mean blood pressure increased in the LPHS group (109 6 13/70 6 9 versus 116 6 6/71 6 5 mmHg). Still, the only patient with hypertensive medication in this group could stop this medication, due to better regulation of his blood pressure (Supplementary data, Table S1 ).
Pooled data from other published case reports
A total of 136 studies were found to apply to our research question (49 in PubMed). We subtracted 32 duplicates. After screening titles and abstracts, we found one case series with four patients and one case report exploring the effect of RDN on kidney-related pain in LPHS (Supplementary data, Tables  S2 and S3 ). Data about the use of analgesic medication could be extracted [17, 18] . However, in the case series, the VAS was based on a quality-of-life assessment scale (European Quality of Life 5-Dimensions questionnaire) and, for our research question, not eligible to assess perceived pain [18] . The other case report was by Gambaro et al., [17] in which no baseline VAS was published. We found two case reports about RDN in ADPKD, of which one was from our centre (Supplementary data, Tables S2 and S3) [16, 19] . The second report was published by Shetty et al. [19] , from which VAS and number of classes of analgesic medication could be extracted. Follow-up data on kidney function were lacking in all case reports. The pooled effect of RDN on decline in the number of classes of analgesic medication at 6 months in patients with LPHS and ADPKD was more pronounced, with a median decline of À1.0 (À2.0 -0.0) pills (P ¼ 0.010) and À2.0 (À2.5 to À0.5) pills (P ¼ 0.066) (Supplementary data, Table S4 ).
D I S C U S S I O N
This pilot study reports on the largest data set of results of percutaneous catheter-based RDN for the treatment of kidneyrelated pain in patients with LPHS and ADPKD. The results suggest that a reduction of pain occurred despite the fact that the use of analgesic medication decreased. Our data also suggest that this effect is sustained, at least for 12 months.
There are only a few case reports that found RDN may result in pain relief and reduction in the use of analgesics in patients with kidney-related pain [16] [17] [18] [19] . Our results are in line with those reports. However, comparison of the various reports is difficult because of the lack of standardization in pain assessment. A difference in VAS of !11 mm is considered to be of clinically significant importance [28] , which was the case in both the LPHS and ADPKD group. The reduction in analgesic drug use is also of interest and of particular relevance in ADPKD. Acetaminophen (paracetamol) is often insufficient, non-steroidal anti-inflammatory agents are contraindicated in patients with CKD and opioids are associated with relevant side effects [7] . Indeed, 6 of the 11 patients were on opioids. Some patients reported difficulties in reducing and stopping opioids because of physical and mental dependency, and needed professional guidance and support for that. We believe that the sustained effect (up to 12 months), the reduction in medication use and the reported difficulties in stopping opioids give support to the idea that the effect of RDN on pain is real. Obviously, we cannot rule out a placebo effect since a sham control arm was missing.
LPHS is often a difficult to treat medical condition. The precise pathogenesis is uncertain. Psychological evaluation is also recommended. Taba et al. [3] recently reviewed possible therapies for kidney-related pain in patients with LPHS. Minimally invasive therapies like bupivacaine infusion and a celiac plexus block gave inconclusive results on efficacy and safety. More invasive methods such as surgical RDN and kidney autotransplantation were reported to have higher success rates, but can be associated with relevant complications. Further, recurrence of pain after surgical RDN can be up to 75% after 12 months [3] , which is in contrast to our study. Moreover, percutaneous RDN would be much easier and safe to repeat for recurrence of pain.
For ADPKD, several approaches have been studied to reduce perceived pain. Tolvaptan, a vasopressin V2 receptor antagonist, which reduces cysts growth, may be helpful to reduce acute pain events [29] . More invasive procedures include percutaneous nerve blocks, transcatheter arterial embolization (TAE) and finally nephrectomy [8] . Percutaneous catheter-based RDN may therefore be an alternative in both disease conditions, as it is less invasive with a low complication rate. However, it is important to emphasize that our ADPKD population was highly selected and only found eligible when a celiac plexus block did not reduce the pain [30] . Presently, RDN is mainly applied in patients with so-called resistant hypertension. There is no specific pathophysiologic argument for that [31] . Earlier, we hypothesized that patients with kidney injury were more likely to have increased activity of the renal nerves and therefore could benefit from RDN [32] [33] [34] . Indeed, all ADPKD patients were on antihypertensive drugs and showed a decrease in blood pressure and in the number of antihypertensive drugs after RDN, despite the fact that most of these patients were only treated unilaterally. However, the observed decline in blood pressure may also be explained, partially, due to better pain control. There was a small overall reduction in renal function 6 months after RDN, assessed as eGFR. This seems to be mainly explained by one LPHS patient. Unfortunately, no repeat measurements are available in this patient. In our study, patients with reduced renal function at baseline were pre-and post-hydrated according to our hospital protocol for preventing contrast nephropathy. Other possible explanations for the decline in renal function are lower perfusion of the kidney due to a decline in blood pressure, normal variation over time or progression of the underlying kidney disease. Obviously, in future studies eGFR should be closely monitored.
Some limitations of the study need to be discussed. First, this study should be considered as a pilot study. It lacks a control group and has a small sample size. Second, the effect on pain showed great variability, that is, in some patients there was little or no effect, while in others a substantial effect was found. All procedures were done with the Medtronic Symplicity device. It is now clear that, with this device, a highly variable degree of denervation is obtained [35, 36] . Also, the location in the renal artery of application and the number of ablation points seem to be of critical importance [36, 37] . So, it is possible that the variability in the observed effect is partially explained by a variable degree of completeness of denervation. Further, our data seem to suggest that the effect on pain increases over time. Third, there could have occurred regression to the mean, but patients had experienced pain with a median duration of 1.5 years, which was at least 3 months stable. In addition, serious adverse events related to the RDN procedure were not reported.
In conclusion, the present data suggest that catheterbased RDN can have a beneficial effect on kidney-related pain and the use of analgesic medication in patients with LPHS and ADPKD. This needs further exploration, as alternative strategies in these disease conditions are insufficient, associated with side effects and/or (much) more invasive. The next study on this subject should be a randomized, preferably sham-controlled clinical study in order to determine whether catheter-based RDN is a meaningful addition to the treatment options in these often difficult to treat patients.
S U P P L E M E N T A R Y D A T A
Supplementary data are available online at http://ndt.oxford journals.org.
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R E F E R E N C E S A B S T R A C T
Background. Taurolidine citrate with heparin (Taurolock/Hep) is a promising central venous catheter lock solution. Despite its universal use among our hemodialysis patients, the prevalence of catheter malfunction was high. We aimed to compare Taurolock/Hep and taurolidine citrate with urokinase (Taurolock/U) as a catheter lock solution in order to identify whether either solution could reduce catheter-related dysfunction. Methods. In this prospective, randomized, controlled trial, patients were randomized to receive either Taurolock/Hep or Taurolock/U and were followed for 6 months. Episodes of acute catheter thrombosis, requirement of recombinant tissue plasminogen activator (rt-PA) and incidence of catheterrelated blood stream infection (CRBSI) were recorded, along with dialysis adequacy (Kt/V), blood flow rates (BFRs) and adverse events.
Results. There were 93 inclusions (85 patients) in the Taurolock/Hep group and 84 inclusions in the Taurolock/U group (79 patients). Three catheters were removed in the Taurolock/Hep group because of acute thrombosis, while no catheter was removed for the same reason in the Taurolock/U group. The total number of all-causes catheter exchange (acute thrombosis and CRBSI) was significantly lower in Taurolock/U group (P ¼ 0.028). rt-PA was used significantly less often in the Taurolock/U group than in the Taurolock/Hep group
